Dapagliflozin suitable adjunct therapy to improve body composition in patients with type 2 diabetes

The study revealed the following findings:

· After 24 months, the mean change in HbA1c in the sitagliptin, dapagliflozin, and lobeglitazone groups was –0.81 ± 0.21%, –1.05 ± 0.70%, and –1.08 ± 0.98%.

· Dapagliflozin treatment significantly lowered systolic blood pressure by 5.5 mmHg and alanine aminotransferase levels.

· Dapagliflozin and lobeglitazone treatment significantly reduced proteinuria and insulin resistance.

· Dapagliflozin reduced whole body fat percentage by 1.2%, whereas sitagliptin and lobeglitazone raised it by 1.1% and 1.8%, respectively.

· In the dapagliflozin group, there was an increase in the whole-body muscle percentage and a decrease in the lobeglitazone group.

· The safety profiles of the three treatments were comparable.

All three drugs -- sitagliptin, dapagliflozin and lobeglitazone -- displayed comparable safety profiles and good glucose-lowering efficacy.

"In terms of urinary protein excretion, blood pressure, and body composition, dapagliflozin therapy demonstrated significant advantages," the researchers wrote in their study.

"Dapagliflozin may be a suitable therapy to improve body composition and cardiometabolic profiles," they concluded.

Reference:

Hwa Hong J, Sung Moon J, Seong K, Lim S. Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: third agent study. Diabetes Res Clin Pract. 2023 Aug 11:110872. doi: 10.1016/j.diabres.2023.110872. Epub ahead of print. PMID: 37574137.